ArticleCNS neuroscience & therapeutics2026
Dihydroartemisinin Alleviates Neuronal Damage and Seizures in Epileptic Mice by Inhibiting Ferroptosis via the SIRT1/FOXO1/SLC7A11/GPX4 Pathway.
Article in CNS neuroscience & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- miRNA-Mediated Regulation of Ferroptosis in Neurological Disorders: Mechanisms and Therapeutic Implications.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundEpilepsy represents a prevalent neurological disorder. Currently, ferroptosis has been reported to be intricately linked to epilepsy onset and progression. Dihydroartemisinin (DHA) can inhibit the level of ferroptosis in various diseases. Therefore, the present study investigated whether DHA could inhibit seizures and display neuroprotective impacts by impeding ferroptosis.
methodsIn the KA-induced epileptic mouse model, the effects of DHA on epileptic behavior, cognitive function, and hippocampal neuronal damage were observed. Using both in vivo and in vitro models, the impact of DHA on neuronal injury and ferroptosis-related markers was investigated. Techniques including molecular docking, Western Blot, immunofluorescence, and CHIP-qPCR were utilized to analyze the regulatory mechanism of DHA on ferroptosis in epilepsy. Finally, brain tissue samples from patients with temporal lobe epilepsy (TLE) were collected to validate the expression of ferroptosis-related markers.
resultsOur experimental results showed that DHA attenuated seizures, hippocampal neuronal damage, and memory and learning deficits in epileptic mice. Moreover, DHA inhibited ferroptosis by activating solute carrier family 7 member 11 (SLC7A11) and glutathione peroxidase 4 (GPX4) expression in vivo and in vitro. Subsequently, we found that DHA activated SIRT1 expression in the mouse hippocampus, leading to a decrease in the acetylation level of forkhead box O1 (FOXO1), thereby increasing the transcriptional activity of SLC7A11. Finally, our findings provide preliminary clinical support for the association between ferroptosis and TLE.
conclusionIn summary, our findings indicate that DHA may have antiepileptic and neuroprotective benefits by suppressing ferroptosis through the SIRT1/FOXO1/SLC7A11/GPX4 signaling pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.